Dr Reddy's Gets USFDA EIR for Visakhapatnam Units

Share:    

Aug 12, 2024 10:22

Dr Reddy's Laboratories has received an Establishment Inspection Report (EIR) from the USFDA for its formulations manufacturing units in Visakhapatnam, classifying the facilities to voluntary action indicated.
New Delhi, Aug 12 (PTI) Dr Reddy's Laboratories Ltd on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its formulations manufacturing units at Duvvada in Visakhapatnam, classifying the facilities to voluntary action indicated.

The USFDA has classified the company's formulations manufacturing facilities (FTO-7 & FTO-9) in Duvvada, as Voluntary Action Indicated (VAI) and concluded that the inspection is "closed", Dr Reddy's Laboratories Ltd said in a regulatory filing.


Earlier, the USFDA had issued a Form 483 with two observations to the two units following inspection which was conducted from May 8 to May 17, 2024.

In May, Dr Reddy's had stated that it would address the issue within the stipulated timeline.

As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Share:    

TODAY'S MOST TRADED COMPANIES

  • Company Name
  • Price
  • Volume

See More >

Moneywiz Live!

Home

Market News

Latest News

International Markets

Economy

Industries

Mutual Fund News

IPO News

Search News

My Portfolio

My Watchlist

Gainers

Losers

Sectors

Indices

Forex

Mutual Funds

Feedback